Mesothelioma arises predominantly in the linings of the lungs or abdomen and is intimately connected to asbestos exposure, a factor that has rendered this malignancy notoriously difficult to treat. Despite approximately 2,700 new diagnoses annually in the UK, prognosis remains grim, with survival rates and available treatment strategies offering limited success. Traditional therapies fail to adequately address the biological heterogeneity of this cancer, underscoring the urgent need for novel, personalized interventions.

Central to this trial, known as SELECTmeso1, is the use of targeted cancer therapies designed to exploit specific genetic vulnerabilities within tumor cells. This approach addresses the problem of variable treatment efficacy by stratifying patients based on identifiable genetic biomarkers, thus aligning therapeutic strategies with the molecular underpinnings of each patient’s disease. Trials like SELECTmeso1 embody the forefront of precision oncology, promising more effective and less toxic interventions.

The project is a collaboration between esteemed institutions including the NIHR Biomedical Research Centres in Leicester and Southampton, with the Southampton Clinical Trials Unit managing operations and oversight. Backed financially by Asthma + Lung UK, this research initiative emphasizes the growing recognition within the medical community of the importance of precision medicine in oncology, especially for diseases with limited therapeutic options like mesothelioma.

Professor Dean Fennell, Chair of Thoracic Medical Oncology at the University of Leicester and lead investigator, highlights the crux of the personalized treatment paradigm: understanding the cancer’s unique genetic landscape. Nearly 50% of mesothelioma patients exhibit a deletion of the MTAP gene, a genetic anomaly that is intricately linked with more aggressive tumor behavior and resistance to conventional therapies. This genetic deletion simultaneously presents a distinctive therapeutic target.

The trial focuses on exploiting the absence of the MTAP gene to disrupt the cancer cells’ growth machinery selectively. In healthy cells, the MTAP gene is involved in critical metabolic pathways, but its deletion in cancer cells creates a biochemical dependency that can be targeted pharmacologically. The investigational drug, Navlimetostat (also referenced as BMS-986504), developed by pharmaceutical giant Bristol Myers Squibb, is a first-in-class PRMT5 inhibitor designed to exploit this metabolic vulnerability, thereby selectively inducing cancer cell death while sparing healthy tissue.

Navlimetostat operates by inhibiting protein arginine methyltransferase 5 (PRMT5), an enzyme crucial to the survival of cancer cells deficient in MTAP. By blocking PRMT5, Navlimetostat disrupts methylation-dependent processes vital to tumor cell proliferation and survival, effectively ‘starving’ the cancer at a molecular level. Early phase studies in other malignancies have shown promising anti-tumor activity and manageable safety profiles, laying a robust foundation for its evaluation in mesothelioma.

The SELECTmeso1 phase of the trial recruits patients with relapsed mesothelioma who test positive for the MTAP gene deletion. The trial administers Navlimetostat orally in three-week cycles, continuing up to six months. Researchers monitor both tumor response and patient tolerance meticulously, aiming to affirm the drug’s efficacy and safety within this highly specific patient subgroup.

This trial represents the initial stage of a larger adaptive platform study intending to evaluate multiple targeted agents against various genetic biomarkers across the spectrum of mesothelioma cases. By adopting a platform model, SELECTmeso aims to streamline clinical investigation, allowing simultaneous testing of several therapeutic candidates tailored to genetic signatures in patients’ tumors, thereby accelerating the pace of discovery and clinical translation.

Looking to the future, the platform design will incorporate molecular profiling of tumor samples to guide patient enrollment across sub-trials, each exploring a drug matched to a distinct biomarker. Such precision trials could transform the clinical landscape, enabling oncologists to offer bespoke therapies with improved outcomes versus the current ‘one-size-fits-all’ approach. Through this strategy, SELECTmeso1 pioneers a new chapter in mesothelioma treatment.

Dr. Samantha Walker of Asthma + Lung UK emphasizes the transformative potential of this research, especially given the dismal survival statistics and lack of curative options for mesothelioma patients. The advancement of targeted therapies has altered the natural history of multiple cancers, and the hope is that SELECTmeso1 will similarly deliver breakthroughs for this challenging disease, ultimately informing standard clinical practice worldwide.

The trial has already commenced recruitment at Leicester Royal Infirmary and will expand to ten additional UK hospitals, enrolling up to 30 patients for this initial evaluation. If successful, this could lay the groundwork for larger, practice-changing trials and establish a template for personalized cancer treatment paradigms not only for mesothelioma but also for other malignancies characterized by genetic heterogeneity.

In sum, the SELECTmeso1 trial exemplifies the cutting-edge intersection of genomics and oncology, demonstrating how understanding cancer’s molecular vulnerabilities can inform smarter, targeted treatments. It embodies the hope and progress achievable through collaborative research, innovative drug design, and precision medicine to improve survival and quality of life for patients facing devastating diagnoses.

Subject of Research: People

Article Title: Personalized Targeted Therapy Trial for Mesothelioma Opens New Frontiers in Cancer Treatment

News Publication Date: Not explicitly stated in source content

Web References:

• Leicester Biomedical Research Centre
• SCTU website
• Asthma + Lung UK
• MiST Trial Article
• CONFIRM Trial News
• NERO Trial News

References:
Cancer Research UK statistics on mesothelioma incidence and survival
Details of Navlimetostat (BMS-986504) as a first-in-class PRMT5 inhibitor by Bristol Myers Squibb

Image Credits: University of Leicester

Keywords: Mesothelioma, Targeted therapy, Personalized medicine, MTAP gene deletion, Navlimetostat, PRMT5 inhibitor, Clinical trial, Cancer research, Genetic biomarkers, Precision oncology, Cancer treatment, Drug development

Pleural mesothelioma, primarily caused by asbestos exposure, has long challenged oncologists due to its poor prognosis and resistance to conventional therapies. The urgent need for more effective treatment strategies has driven scientists to explore novel agents capable of halting or reversing tumor progression. Cephalomannine, a taxane compound structurally related to paclitaxel, emerged as a standout candidate during an extensive drug screening process aimed at identifying molecules with high activity against mesothelioma cells.

The research team conducted rigorous in vivo experiments using NOD-SCID mice implanted with human PM xenografts to assess the therapeutic efficacy of cephalomannine in a living system. Mice treated with cephalomannine at a dosage of 2 mg/kg body weight exhibited a significantly prolonged median overall survival (OS) of 75 days compared to only 55 days in the vehicle-treated control group. This statistically significant improvement underscores cephalomannine’s ability to meaningfully extend survival in an aggressive cancer model.

In addition to animal studies, the investigators delved into the molecular and cellular impacts of cephalomannine in vitro, using two different cell lines: REN, a human pleural mesothelioma-derived line, and MeT-5A, a non-malignant mesothelial cell line serving as a control. This dual-cell approach allowed for a nuanced understanding of cephalomannine’s selective effects on cancerous versus normal cells, critical for evaluating therapeutic safety and specificity.

One of the key revelations from the in vitro experiments was the alteration in cellular metabolism induced by cephalomannine. The compound markedly decreased the oxygen consumption rate (OCR) in REN cells, indicating a disruption in mitochondrial respiration. Such an effect suggests that cephalomannine impairs the energy production pathways cancer cells rely on, potentially triggering metabolic stress and sensitizing tumors to apoptotic signals.

Complementing the metabolic findings, cephalomannine treatment led to a significant increase in the production of reactive oxygen species (ROS) within mesothelioma cells. Elevated ROS levels, while damaging at high concentrations, can act as a double-edged sword in cancer cells by inducing oxidative stress that contributes to cell death. This pro-oxidative effect of cephalomannine provides a mechanistic insight into its cytotoxicity.

Further molecular analyses revealed that cephalomannine modulates key regulators of apoptosis, the programmed cell death pathway often dysregulated in cancer. Specifically, cephalomannine increased the protein expression of BAX, a pro-apoptotic molecule, while decreasing Bcl-2, an anti-apoptotic counterpart, in the REN cell line. This shift in the BAX/Bcl-2 ratio favors apoptotic signaling, promoting the elimination of malignant cells.

Interestingly, despite these pro-death effects, cephalomannine did not activate inflammatory pathways typically associated with cancer cell responses. The levels of interleukin-18 (IL-18), a cytokine marker for inflammasome activation, remained unchanged, suggesting that cephalomannine’s anticancer activity is primarily driven through apoptosis rather than inflammation. This selective mechanism may reduce potential side effects linked to inflammatory responses.

While fludarabine and crenolanib, two other agents tested in parallel, failed to demonstrate significant efficacy in the in vivo mesothelioma model, cephalomannine clearly stood out as a potent therapeutic candidate. These comparative results highlight the importance of thorough preclinical screening to identify truly effective anti-cancer agents.

The collective findings from this study illuminate cephalomannine as a multifaceted anticancer compound that disrupts mitochondrial function, induces oxidative stress, and triggers apoptosis selectively in mesothelioma cells. This multifactorial mechanism makes it a promising candidate for further development, either as a monotherapy or in combination with existing chemotherapeutics to overcome resistance.

Moreover, this work opens new avenues for investigating novel molecular targets within the metabolic and apoptotic pathways modulated by cephalomannine. Understanding these pathways in greater detail could lead to the design of even more effective derivatives or combinatorial regimens tailored for mesothelioma treatment.

Given the limited treatment options currently available for pleural mesothelioma patients, these findings hold significant clinical potential. If future clinical trials confirm cephalomannine’s safety and efficacy in humans, it could revolutionize the standard of care and improve long-term outcomes for individuals afflicted with this aggressive cancer.

In sum, this study not only brings cephalomannine to the forefront of mesothelioma research but also exemplifies the power of integrating in vivo survival data with detailed mechanistic insights. Such an approach enhances our understanding of cancer biology and accelerates the translation of laboratory discoveries into tangible therapeutic advancements.

Researchers are now poised to embark on the next stage of investigations, including dose optimization, toxicity profiling, and clinical trials, to fully harness cephalomannine’s anticancer potential. The ongoing quest to outsmart mesothelioma has gained a formidable new contender, signaled by the promise of this remarkable compound.

This pioneering work stands as a testament to the relentless pursuit of innovative solutions in cancer therapy, demonstrating that even well-known molecules can reveal unexpected efficacies in challenging malignancies like pleural mesothelioma.

As the scientific community rallies around these findings, the hope for effective, targeted treatments for mesothelioma soars, offering patients and clinicians new reasons to look forward to a future with better therapeutic options.

Subject of Research: The anticancer effects and mechanisms of action of cephalomannine in pleural mesothelioma cells.

Article Title: Cephalomannine as in vitro and in vivo anticancer agent in mesothelioma cells: mechanisms of action

Article References:
Morani, F., Dell’Anno, I., Daga, A. et al. Cephalomannine as in vitro and in vivo anticancer agent in mesothelioma cells: mechanisms of action. BMC Cancer 25, 1625 (2025). https://doi.org/10.1186/s12885-025-14902-6

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14902-6